Bolus injection (2–4min) versus short-term (10–20min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial

Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study

“…chemotherapy, we used historical controls. The two combinations (MFL and FLv) of chemotherapy, both based on biochemical modulation of 5-FU, were equally effective with respect to survival and response rates in one trial (Glimelius et al, 1998). It is therefore reasonable to consider these two combinations as equal and these patients thus received 'golden standard' chemotherapy during their treatment period.…”

“…In all, 18 patients (nine women, nine men, mean age 56 years, range 36 -69) treated for advanced colorectal adenocarcinoma within the Nordic chemotherapy trials (Nordic Gastrointestinal Tumour Adjuvant Therapy Group, 1992;Glimelius, 1993;Glimelius et al, 1998) were randomly selected as a reference group. The selection was made without any knowledge of survival.…”

Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer

“…Modulated 5-FU bolus regimens have until the year 2000 been the reference treatment in the US and in the Nordic countries. The Nordic FLv regimen consists of a short (3 min) bolus injection of 500 mg/m 2 5-FU followed by a bolus injection of 60 mg/m 2 FA 30 min later (9,10). In a compassionate use study we added oxaliplatin to our current Nordic 5-FU leucovorin schedule (Nordic FLOX) (11).…”

Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report

“…Across trial comparisons also support the notion that infused 5-FU/LV regimens are somewhat more effective and less toxic than bolus regimens [16 Á/19]. Efficacy and toxicity of bolus Nordic 5-FU/LV is seemingly comparable to infused regimens [20,21]. However, there is not yet any publication on a direct comparison between this regimen and infused 5-FU/LV, but results from a randomized trial comparing these regimens when combined with irinotecan (NordicVI) are awaited.…”